Hangzhou Weiruibao Biopharmaceutical

Hangzhou Weiruibao Biopharmaceutical is an innovative biotechnology company headquartered in Hangzhou, China, specializing in the development of next-generation small molecule therapeutics for oncology. The company focuses on addressing unmet medical needs through its proprietary drug discovery platform, with a particular emphasis on synthetic lethality and DNA damage response mechanisms. Its lead program, WRB-082, is a highly selective USP1 inhibitor currently in the IND-enabling or early clinical stage for the treatment of advanced solid tumors. Led by a team of industry veterans, Weiruibao is committed to advancing a diverse pipeline of first-in-class and best-in-class drug candidates. The company operates within the vibrant Hangzhou pharmaceutical ecosystem, benefiting from local R&D infrastructure and investment.